Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-17
2007-07-17
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S331000
Reexamination Certificate
active
10489056
ABSTRACT:
The present invention provides compounds of formula (I):wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
REFERENCES:
patent: 4576952 (1986-03-01), Hurst et al.
patent: 4621089 (1986-11-01), Ward et al.
patent: 4670432 (1987-06-01), Ward et al.
patent: 4719218 (1988-01-01), Bender et al.
patent: 4794114 (1988-12-01), Bender et al.
patent: 4985444 (1991-01-01), Shiokawa et al.
patent: 5145858 (1992-09-01), Adams et al.
patent: 5155114 (1992-10-01), Shiokawa et al.
patent: 5204346 (1993-04-01), Shiokawa et al.
patent: 5234930 (1993-08-01), Shiokawa et al.
patent: 5296490 (1994-03-01), Shiokawa et al.
patent: 5300478 (1994-04-01), Michaely et al.
patent: 5498774 (1996-03-01), Mitsudera et al.
patent: 5552422 (1996-09-01), Gauthier et al.
patent: 5700816 (1997-12-01), Isakson et al.
patent: 5990148 (1999-11-01), Isakson et al.
patent: 6136839 (2000-10-01), Isakson et al.
patent: 6207675 (2001-03-01), Carry et al.
patent: 2004/0176396 (2004-09-01), Biftu et al.
patent: 0 404 190 (1990-06-01), None
patent: 0 404 190 (1990-06-01), None
patent: 0403251 (1990-06-01), None
patent: 0 379 979 (1990-08-01), None
patent: 0404190 (1990-12-01), None
patent: 0 467 248 (1991-07-01), None
patent: 0 497 258 (1992-01-01), None
patent: 2 757 059 (1998-06-01), None
patent: 2001006877 (1999-06-01), None
patent: EP 0 364 204 (1989-10-01), None
patent: WO 91 00092 (1991-01-01), None
patent: WO 91 19497 (1991-12-01), None
patent: WO 92/10190 (1992-06-01), None
patent: WO 92/10498 (1992-06-01), None
patent: WO 92/10499 (1992-06-01), None
patent: WO 95 00501 (1995-01-01), None
patent: WO 96 06840 (1996-03-01), None
patent: WO 96/16040 (1996-05-01), None
patent: WO 96 21667 (1996-07-01), None
patent: WO 96 31509 (1996-10-01), None
patent: WO 96/34866 (1996-11-01), None
patent: WO 96 41625 (1996-12-01), None
patent: WO 96 41626 (1996-12-01), None
patent: WO 96 41645 (1996-12-01), None
patent: WO 98 56377 (1998-12-01), None
patent: WO 99 12930 (1999-03-01), None
patent: WO 99/58523 (1999-11-01), None
patent: WO 99/59585 (1999-11-01), None
patent: WO 99 64419 (1999-12-01), None
patent: WO 00/26216 (2000-05-01), None
patent: WO 00/52008 (2000-09-01), None
patent: WO 01/00615 (2001-01-01), None
patent: WO 01 00615 (2001-01-01), None
patent: WO 01 14375 (2001-03-01), None
patent: WO 01/96335 (2001-12-01), None
patent: WO 02/16359 (2002-02-01), None
patent: WO 02/18382 (2002-03-01), None
patent: WO 02 18382 (2002-03-01), None
patent: WO 02 48147 (2002-06-01), None
patent: WO 02/048148 (2002-06-01), None
patent: WO 02 066481 (2002-08-01), None
patent: WO 03/00682 (2003-01-01), None
Bosseray et al., PubMed Abstract (Pathol Biol (Paris) 50(8):483-92) Oct. 2002.
Razonable et al., PubMed Abstract (Herpes 10(3):60-5) Dec. 2003.
Vane, J. et al. “Towards a Better Aspirin.” Nature, vol. 367, Jan. 20, 1994, pp. 215-216.
Carter, J. et al. “Recently Reported Inhibitors of Cyclooxygenase-2.” Exp. Opin. Ther. Patents (1998), 8(1), pp. 21-29.
Talley, JJ., “Review, Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis, Selective Inhibitors of Cyclooxygenase-2.” Exp. Opin. Ther. Patents (1997) 7(1), pp. 55-62.
Roy, P., “A New Series of Selective Cox-2 Inhibitors: 5,6-Diarylthiazolo [3,2-b][1,22,4] Triazoles,”Bioorganiz & Med. Chem. Ltrs., vol. 7, No. 1, 1997, pp. 57-62.
Therien, Michael, Synthesis and Biological Evaluation of 5, 6-Diarylimidazo[2.1-b]Thiazole As Selective Cox-2 Inhibitors,Bioorganic&Med. Chem. Ltrs., vol. 7, No. 1, 1997, pp. 47-52.
Akahane, Atsushi, “Discovery of 6-Oxo-3-(2-Phenlypyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinebutanoic Acid (FR 838): A Novel Xanthine Adenosine A1Receptor Antagonist with Potent Diuretic Activity,”Journal of Medicinal Chemistry, vol. 42, No. 5, 1999, pp. 779-783.
Talley, John J., 5 Selective Inhibitors of Cyclooxygenase-2 (COX-2)Progress in Medicinal Chemistry, vol. 36, (1999): pp. 201-234.
Boehm, J.C., et al. “1-Substituted 4-Aryl-5-pyridinylimidazoles: A New Class of Cytokine Suppressive Drugs with Low 5-Lipoxygenase and Cyclooxygenase Inhibitor Potency.” J. Med. Chem. 1996, 39, pp. 3929-3937.
Hanson, G.J., et al. “Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis, Inhibitors of p38 kinase.” Expert Opinion Ther. Patents, 1997, 7(7):729-733.
Gudmundsson Kristjan
Johns Brian A
Phillips Valerie L.
Rao Deepak
SmithKline Beecham Corporation
LandOfFree
Imidazo-pyridine derivatives for use in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazo-pyridine derivatives for use in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazo-pyridine derivatives for use in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3725070